27 June 2014 in Journal of the American Chemical Society
18 November 2015 in Natural Product Reports
Direct capture of drug–target complexesin situby using affinity-based probes allows target identification of natural products and bioactive compounds, even if the binding is reversible with moderate affinity.
8 March 2021 in Nature Nanotechnology
22 November 2016 in Journal of the American Chemical Society
7 August 2017 in Angewandte Chemie International Edition
1 August 2023 in Chemical Society Reviews
Over the past decade, remarkable advances have been witnessed in the development of small-molecule probes. These molecular tools have been widely applied for interrogating proteins, pathways and drug–target interactions in preclinical research. While novel structures and designs are commonly explored in probe development, the clinical translation of small-molecule probes remains limited, primarily due to safety and regulatory considerations. Recent synergistic developments – interfacing novel chemical probes with complementary analytical technologies – have introduced and expedited diverse biomedical opportunities to molecularly characterize targeted drug interactions directly in the human body or through accessible clinical specimens (e.g., blood and ascites fluid). These integrated developments thus offer unprecedented opportunities for drug development, disease diagnostics and treatment monitoring. In this review, we discuss recent advances in the structure and design of small-molecule probes with novel functionalities and the integrated development with imaging, proteomics and other emerging technologies. We further highlight recent applications of integrated small-molecule technologies for the molecular analysis of drug–target interactions, including translational applications and emerging opportunities for whole-body imaging, tissue-based measurement and blood-based analysis.